Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PulmoPrint fluorescence bronchoscopy study
NL-OMON61536Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: In vivo fluorescent signal of malignant lesions. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61536.